• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings

    11/17/22 2:32:02 PM ET
    $ARDX
    $BABA
    $BBWI
    $DZSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate
    Real Estate
    Get the next $ARDX alert in real time by email

    U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday.

    The Dow traded down 0.18% to 33,491.86 while the NASDAQ fell 0.54% to 11,123.49. The S&P 500 also fell, dropping, 0.56% to 3,936.57.

    Also check this: Nasdaq Drops Sharply, But Market Volatility Decreases


    Leading and Lagging Sectors


    Health care shares rose by 0.1% on Thursday. Leading the sector was strength from Ardelyx, Inc. (NASDAQ:ARDX) and OmniAb, Inc. (NASDAQ:OABI).


    In trading on Thursday, utilities dipped by 1.8%.


    Top Headline

     

    Alibaba Group Holding Ltd (NYSE:BABA) reported better-than-expected earnings for its second quarter, while sales missed estimates. The company also announced its board approved to upsize its share repurchase program by another $15 billion.

    Alibaba said third-quarter revenue increased 3% year-over-year to RMB207,176 million ($29.12 billion), which missed average analyst estimates of $29.45 billion. The China-based e-commerce company reported quarterly earnings of $1.82 per share, which beat average estimates of $1.64 per share.


    Equities Trading UP

     

    • Bath & Body Works, Inc. (NYSE:BBWI) shares shot up 23% to $38.16 after the company reported better-than-expected Q3 results.
    • Shares of Ardelyx, Inc. (NASDAQ:ARDX) got a boost, shooting 47% to $1.7893 after the company announced the FDA Advisory Committee voted 9-to-4 that the benefits of XPHOZAH outweigh its risks for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.
    • Elevate Credit, Inc. (NYSE:ELVT) shares were also up, gaining 71% to $1.81 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67 million.

     

    Equities Trading DOWN

    • Editas Medicine, Inc. (NASDAQ:EDIT) shares tumbled 16% to $10.33 after the company announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101.
    • Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) were down 26% to $2.36 after the company announced pricing of a public offering of 22,613,307 shares of common stock at a price of $2.60 per share.
    • DZS Inc. (NASDAQ:DZSI) was down, falling 18% to $11.20 after the company announced pricing of a roughly $28.8 million public offering of 3,377,315 shares at a price of $11.50 per share


    Also check out: Target, Holley, Ferroglobe And Other Big Losers From Wednesday


    Commodities

    In commodity news, oil traded down 4.4% to $81.79 while gold traded down 0.9% at $1,760.20.


    Silver traded down 2.8% to $20.92 on Thursday while copper fell 2.3% to $3.6880.


    Euro zone


    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.42%, London’s FTSE 100 fell 0.06% while Spain’s IBEX 35 Index fell 0.75%. The German DAX rose 0.23%, French CAC 40 fell 0.47% and Italy’s FTSE MIB Index fell 0.78%.


    The Eurozone consumer price inflation fell to 10.6% year-over-year in versus a preliminary estimate of 10.7%, while construction output in the region increased 1% year-over-year in September. Passenger car registrations in the European Union surged 12.2% year-over-year to 745,855 units in October.

    Spanish trade deficit increased to EUR 6.98 billion in September from EUR 2.39 billion in the year-ago.

     

    Asia Pacific Markets


    Asian markets closed lower on Thursday, with the Japan’s Nikkei dropping 0.35% and Hong Kong’s Hang Seng Index falling 1.15%. China’s Shanghai Composite Index fell 0.15%.

    Hong Kong’s unemployment rate dropped to 3.8% in the three months ending October. Foreign direct investment into China jumped 14.4% from a year ago to CNY 1.09 trillion during the first ten months of the year. The unemployment rate in Australia fell to 3.4% in October from 3.5% in September. Exports from Japan jumped by 25.3% year-over-year to JPY 9,001.5 billion, while imports to the country climbed 53.5% to a new high of JPY 11,164.8 billion during October.


    Economics

     

    • US jobless claims dropped by 4,000 to 222,000 on the week ending November 12th, compared to market estimates of 225,000.
    • The Philadelphia Fed Manufacturing Index declined to -19.4 in November from -8.7 in the previous month, recording the weakest level since May 2020.
    • Housing starts in the US dropped 4.2% month-over-month to an annualized rate of 1.425 million in October, while building permits fell 2.4% to an annual rate of 1.526 million.
    • US natural-gas supplies rose 64 billion cubic feet last week, the EIA said.

     

    Check out this: Target Earnings Miss Estimates, Here's A Look At Recent Price Target Cuts By The Most Accurate Analysts


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 100,054,790 cases with around 1,101,370 deaths. India confirmed a total of at least 44,668,290 cases and 530,540 deaths, while France reported over 37,217,030 COVID-19 cases with 158,000 deaths. In total, there were at least 641,668,210 cases of COVID-19 worldwide with more than 6,620,360 deaths.

    Get the next $ARDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARDX
    $BABA
    $BBWI
    $DZSI

    CompanyDatePrice TargetRatingAnalyst
    Alibaba Group Holding Limited
    $BABA
    1/21/2026$190.00Neutral → Buy
    Arete
    Bath & Body Works Inc.
    $BBWI
    1/14/2026$24.00Hold
    Jefferies
    Ardelyx Inc.
    $ARDX
    1/9/2026Neutral → Overweight
    Piper Sandler
    Alibaba Group Holding Limited
    $BABA
    1/8/2026$231.00 → $225.00Buy
    Jefferies
    Alibaba Group Holding Limited
    $BABA
    1/8/2026$200.00 → $180.00Overweight
    Morgan Stanley
    Bath & Body Works Inc.
    $BBWI
    1/8/2026$21.00Buy → Hold
    Deutsche Bank
    Bath & Body Works Inc.
    $BBWI
    12/10/2025Neutral
    Guggenheim
    Alibaba Group Holding Limited
    $BABA
    12/9/2025$172.00Buy → Neutral
    Arete
    More analyst ratings

    $ARDX
    $BABA
    $BBWI
    $DZSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Finance Higa Tomohiro was granted 29,250 shares, increasing direct ownership by 31% to 123,221 units (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    2/5/26 6:03:28 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Tingley Whittemore was granted 48,750 shares, increasing direct ownership by 28% to 223,778 units (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    2/5/26 6:02:44 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Ali Faraz was granted 158,600 shares, increasing direct ownership by 53% to 458,266 units (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    2/5/26 6:02:09 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARDX
    $BABA
    $BBWI
    $DZSI
    SEC Filings

    View All

    SEC Form 6-K filed by Alibaba Group Holding Limited

    6-K - Alibaba Group Holding Ltd (0001577552) (Filer)

    2/4/26 4:01:17 PM ET
    $BABA
    Real Estate

    SEC Form S-8 filed by Tenaya Therapeutics Inc.

    S-8 - Tenaya Therapeutics, Inc. (0001858848) (Filer)

    2/3/26 4:06:14 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

    8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

    1/30/26 5:06:08 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARDX
    $BABA
    $BBWI
    $DZSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bath & Body Works Declares Cash Dividend

    COLUMBUS, Ohio, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE:BBWI) announced today the declaration of its regular quarterly dividend of $0.20 per share payable on March 6, 2026, to shareholders of record at the close of business on February 20, 2026. ABOUT BATH & BODY WORKS: Home of America's Favorite Fragrances®, Bath & Body Works is a global leader in personal care and home fragrance, including top-selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap. Powered by agility and innovation, the company's predominantly U.S.-based supply chain enables it to deliver quality, on-trend luxuries a

    2/6/26 8:30:00 AM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

    WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2025. The call will include commentary from members of the Ardelyx Executive Leadership Team including Mike Raab, President and Chief Executive Officer, Sue Hohenleitner, Chief Financial Officer, Eric Foster, Chief Commercial Officer, and Laura

    2/5/26 8:00:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Receives New Patent for Tenapanor

    WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,539,299 titled "Oral Formulations of Tenapanor" with an expiration date of November 26, 2042. The patent relates to the formulation of tenapanor and covers the commercial formulations of IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The patent will be submitted to the Food and Drug Administration for listing in the Approved Drug Products wit

    2/3/26 8:29:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BABA
    $BBWI
    $DZSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nash Sarah E bought $155,800 worth of shares (10,000 units at $15.58), increasing direct ownership by 4% to 285,522 units (SEC Form 4)

    4 - Bath & Body Works, Inc. (0000701985) (Issuer)

    11/25/25 4:16:41 PM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Director Symancyk James Kevin bought $350,550 worth of shares (22,500 units at $15.58), increasing direct ownership by 126% to 40,379 units (SEC Form 4)

    4 - Bath & Body Works, Inc. (0000701985) (Issuer)

    11/25/25 4:16:42 PM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Director Steinour Stephen D bought $99,528 worth of shares (6,700 units at $14.86), increasing direct ownership by 16% to 48,175 units (SEC Form 4)

    4 - Bath & Body Works, Inc. (0000701985) (Issuer)

    11/24/25 5:09:20 PM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ARDX
    $BABA
    $BBWI
    $DZSI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:37:08 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BABA
    $BBWI
    $DZSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alibaba upgraded by Arete with a new price target

    Arete upgraded Alibaba from Neutral to Buy and set a new price target of $190.00

    1/21/26 8:25:13 AM ET
    $BABA
    Real Estate

    Jefferies resumed coverage on Bath & Body Works with a new price target

    Jefferies resumed coverage of Bath & Body Works with a rating of Hold and set a new price target of $24.00

    1/14/26 8:39:59 AM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Ardelyx upgraded by Piper Sandler

    Piper Sandler upgraded Ardelyx from Neutral to Overweight

    1/9/26 8:23:44 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BABA
    $BBWI
    $DZSI
    Leadership Updates

    Live Leadership Updates

    View All

    Bath & Body Works Outlines Strategic Transformation for Sustainable Growth and Reports 2025 Third Quarter Results

    Launches the Consumer First Formula with four strategic priorities to drive sustainable long-term growthThird-quarter net sales of $1.6 billion, down 1%. Earnings per diluted share of $0.37; Adjusted earnings per diluted share of $0.35Q4 and full-year 2025 guidance lowered reflecting current business trends and continuation of recent macro consumer pressures COLUMBUS, Ohio, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE:BBWI) today reported third quarter 2025 results. Daniel Heaf, chief executive officer of Bath & Body Works, commented, "Today, we are excited to announce a comprehensive transformation plan to revitalize Bath & Body Works across brand, product, and market

    11/20/25 6:55:00 AM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Bath & Body Works Announces Key Leadership Appointments

    Maly Bernstein appointed Chief Commercial Officer to Strengthen Engagement and Performance Across All Channels Samantha Charleston appointed Chief Human Resources Officer to Align People Strategy with Business Priorities  COLUMBUS, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE:BBWI) today announced strategic leadership appointments to deepen expertise and strengthen capabilities required to execute transformation. Maly Bernstein has been appointed Chief Commercial Officer and Samantha Charleston has been appointed Chief Human Resources Officer, both effective Nov. 12.  "As we enter a new era for Bath & Body Works, we're building a next-generation leadership team w

    11/4/25 9:00:00 AM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

    WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective November 4, 2025. Ms. Hohenleitner is a proven financial leader, bringing more than 30 years of experience in corporate finance, strategic planning, investor relations and operations across a variety of therapeutic areas and stages of development. She has a demonstrated track record of driving organizational transformation, building financial strength

    10/13/25 8:30:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BABA
    $BBWI
    $DZSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

    SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

    11/14/24 5:46:12 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

    SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

    11/14/24 4:08:33 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alibaba Group Holding Limited

    SC 13G/A - Alibaba Group Holding Ltd (0001577552) (Filed by)

    11/14/24 4:03:02 PM ET
    $BABA
    Real Estate

    $ARDX
    $BABA
    $BBWI
    $DZSI
    Financials

    Live finance-specific insights

    View All

    Bath & Body Works Declares Cash Dividend

    COLUMBUS, Ohio, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE:BBWI) announced today the declaration of its regular quarterly dividend of $0.20 per share payable on March 6, 2026, to shareholders of record at the close of business on February 20, 2026. ABOUT BATH & BODY WORKS: Home of America's Favorite Fragrances®, Bath & Body Works is a global leader in personal care and home fragrance, including top-selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap. Powered by agility and innovation, the company's predominantly U.S.-based supply chain enables it to deliver quality, on-trend luxuries a

    2/6/26 8:30:00 AM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

    WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2025. The call will include commentary from members of the Ardelyx Executive Leadership Team including Mike Raab, President and Chief Executive Officer, Sue Hohenleitner, Chief Financial Officer, Eric Foster, Chief Commercial Officer, and Laura

    2/5/26 8:00:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

    TN-401 was Well Tolerated at 3E13 vg/kg dose  Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-Up Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary Results SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced interim data

    12/11/25 4:01:00 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care